Baird analyst Jack Allen lowered the firm’s price target on Intellia Therapeutics to $42 from $58 and keeps a Neutral rating on the shares. The analyst said overall, Intellia’s earnings updates were inline with expectations with the two lead products, NTLA-2001 and NTLA-2002, both set to see US INDs this year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NTLA:
- Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress
- Intellia Therapeutics reports Q4 EPS ($1.40), consensus ($1.39)
- Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates
- 2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023
- Intellia Therapeutics initiated with an Overweight at Cantor Fitzgerald